Contributions
Abstract: 135
Type: Educational Session
Abstract Category: N/A
Bladder and bowel dysfunction often occurs in Multiple Sclerosis (MS). In 10% of all newly diagnosed persons with MS (PwMS), bladder symptoms are the first neurological symptom patients experience. The severity of the problems often correlate with the degree of spinal cord involvement.
Looking to the burden of MS, after fatigue and mobility problems, bladder and bowel disorders are the most embarrassing problem for PwMS, and they are even more in primary progressive MS.
Management strategies of bladder and bowel problems are until now mainly medical and increasingly offered by non-urologists. Non-medical interventions need to be included. As treatments can be highly effective, relieving patients of troublesome symptoms and preventing possible neurological exacerbations, it's important to recognize the disorders and being aware of possible treatments depending the disease severity and the PwMS preference.
This course starts with an overview of the neural control of bladder and bowel followed by the pathophysiology of neurogenic bladder and bowel disorders due to MS.
Further on we will focus on the assessment of bladder and bowel disorders; from the importance and advantages of a thoroughly history taken to an overview of scales and exams which can be used to support the assessment.
Finally we will give an overview of treatment options including first-line measures such as pelvic floor reeducation, guiding PwMS in their food and fluid intake, anticholinergics, clean intermittent self-catheterization and the use of desmopressin, as well as potential second-line options such as cannabinoids, botulinum toxin, suprapubic catheters and surgery. Bowel disorders first and second line treatment options from bulging agents, laxantia to trans anal irrigations will also be discussed. Finally the management of side effects of all treatment options will be highlighted.
With this teaching course we want you to help bridging the gap between Neurology and Urology.
Disclosure: Piet Eelen is an invited speaker and member of advisory boards organized by pharma companies (Biogen, Merck, Novartis, TEVA, Sanofi-Genzyme, Roche, Coloplast and BBraun).
Abstract: 135
Type: Educational Session
Abstract Category: N/A
Bladder and bowel dysfunction often occurs in Multiple Sclerosis (MS). In 10% of all newly diagnosed persons with MS (PwMS), bladder symptoms are the first neurological symptom patients experience. The severity of the problems often correlate with the degree of spinal cord involvement.
Looking to the burden of MS, after fatigue and mobility problems, bladder and bowel disorders are the most embarrassing problem for PwMS, and they are even more in primary progressive MS.
Management strategies of bladder and bowel problems are until now mainly medical and increasingly offered by non-urologists. Non-medical interventions need to be included. As treatments can be highly effective, relieving patients of troublesome symptoms and preventing possible neurological exacerbations, it's important to recognize the disorders and being aware of possible treatments depending the disease severity and the PwMS preference.
This course starts with an overview of the neural control of bladder and bowel followed by the pathophysiology of neurogenic bladder and bowel disorders due to MS.
Further on we will focus on the assessment of bladder and bowel disorders; from the importance and advantages of a thoroughly history taken to an overview of scales and exams which can be used to support the assessment.
Finally we will give an overview of treatment options including first-line measures such as pelvic floor reeducation, guiding PwMS in their food and fluid intake, anticholinergics, clean intermittent self-catheterization and the use of desmopressin, as well as potential second-line options such as cannabinoids, botulinum toxin, suprapubic catheters and surgery. Bowel disorders first and second line treatment options from bulging agents, laxantia to trans anal irrigations will also be discussed. Finally the management of side effects of all treatment options will be highlighted.
With this teaching course we want you to help bridging the gap between Neurology and Urology.
Disclosure: Piet Eelen is an invited speaker and member of advisory boards organized by pharma companies (Biogen, Merck, Novartis, TEVA, Sanofi-Genzyme, Roche, Coloplast and BBraun).